Annals of Surgical Oncology

, Volume 3, Issue 6, pp 574–579 | Cite as

Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors

  • Jia-Lin Yang
  • Kim T. Ow
  • Pamela J. Russell
  • John M. Ham
  • Philip J. Crowe
Original Articles


Background: Expression of individual oncogenes may predict outcome in patients with metastatic colorectal cancer (CRC). We studied the oncogene profile in the tumors of patients with CRC and assessed their value as predictors of liver metastases.

Methods: The oncoproteins c-myc, c-erbB-2/neu (c-neu), PCNA and p53, were measured by immunohistochemistry in sections of metastasizing human CRC (n=34) and their liver secondaries as well as in sections of nonmetastasizing CRC (n=25).

Results: The metastasizing primary CRC expressed proliferating-cell nuclear antigen (PCNA), c-neu, and c-myc at significantly higher levels than the nonmetastasizing primary cancer. p53 was also overexpressed in the metastatic group compared with the nonmetastasizing CRC, but this difference was not significant. The frequency of expression of all these markers was similar in the metastasizing primary CRC and the liver secondaries from the same patients. There was no correlation between the expression of the individual markers and histological grade, DNA ploidy, and subsequent local recurrence and lung metastasis and survival. However, when both groups were assessed together, positive expression of c-myc was more likely to occur in poorly differentiated tumors, whereas PCNA expression increased with more advanced Dukes stages.

Conclusion: These results suggest that the overexpression of c-myc, c-neu, PCNA, and p53 may occur in CRC that are likely to metastasise to the liver.

Key Words

Oncorprotein c-myc c-erbB-2/neu PCNA p53 Metastatic colorectal cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fidler IJ, Hart IR. Biologic diversity in metastatic neoplasms—origins and implications.Science 1982;217:998–1001.PubMedGoogle Scholar
  2. 2.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.Cell 1990;61:759–67.CrossRefPubMedGoogle Scholar
  3. 3.
    Rigas B. Oncogenes and suppressor genes: their involvement in colon cancer.J Clin Gastroenterol 1990;12:494–9.PubMedGoogle Scholar
  4. 4.
    Menko FH.Genetics of colorectal cancer for clinical practice. The Netherlands: Kluwer Academic Publishers, 1993:135–6.Google Scholar
  5. 5.
    Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer.N Engl J Med 1994;331:213–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Yang J-L, Crowe PJ, Ow KT, Ham JM, Crouch RL, Russell PJ. DNA flow-cytometric analysis in colorectal cancer: a comparison of metastasising and non-metastasising tumours.J Gastroenterol Hepatol (in press).Google Scholar
  7. 7.
    Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects.Adv Cancer Res 1990;55:87–131.PubMedGoogle Scholar
  8. 8.
    Goh HS, Soong TW, Lee YS, Ho J, Goh CR. c-myc oncogene expression in colorectal cancer: its use in prognosis and role in colorectal carcinogenesis.Ann Acad Med Singapore 1990;19:139–41.PubMedGoogle Scholar
  9. 9.
    Yamaguchi A, Ninomiya I, Ishida T, Nishimura G, Kanno M, Yonemura Y, Miwa K, et al. Immunohistochemical detection of c-myc products in colorectal cancer and proliferative cell rate.Oncology 1992;49:40–4.PubMedGoogle Scholar
  10. 10.
    Rowley S, Newbold KM, Gearty J, Keighley MR, Donovan IA, Neoptolemos JP. Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer.World J Surg 1990;14:545–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Kozma L, Kiss I, Szakall S, Ember I. Investigation of c-myc oncogene amplification in colorectal cancer.Cancer Lett 1994;81:165–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Kapitanovic S, Spaventi R, Poljak L, Kapitanovic M, Pavelic ZP, Gluckman JL, Spaventi S, Pavelic K. High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters.Cancer Detec Prevent 1994;18:97–101.Google Scholar
  13. 13.
    Omori K. DNA content and c-erbB-2 oncoprotein expression in hepatic metastases from colorectal carcinoma in relation to clinicopathologic findings and prognosis.Jpn J Surg 1991;92:1469–79.Google Scholar
  14. 14.
    Tsioulias GJ, Muto T, Morioka Y, Yamamoto T, Mori S. erbB-2 gene expression in colorectal cancer.Jpn J Exp Med 1990;60:343–9.PubMedGoogle Scholar
  15. 15.
    Risio M, Rossini FP. Cell proliferation in colorectal adenomas containing invasive carcinoma.Anticancer Res 1993;13:43–7.PubMedGoogle Scholar
  16. 16.
    Jin Y, Jin Z, Sawada T, Kubota Y, Suzuki K, Watanabe T, Sameshima S, et al. Growth type of colorectal cancer invasion of the proper muscle in relation to DNA ploidy and distribution of PCNA.Jpn J Cancer Chemother 1993;20:784–7.Google Scholar
  17. 17.
    Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.Cancer 1993;71:2454–60.PubMedGoogle Scholar
  18. 18.
    Al-Sheneber IF, Shibata HR, Sampalis J, Jothy S. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer.Cancer 1993;71:1954–9.PubMedGoogle Scholar
  19. 19.
    Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriguez-Martinnez HA, Gutierrez-Diaz ME, et al. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.Virchows Arch 1994;424:187–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Baba S, Ogiwara H, Nakamura T, Teramoto T. Extended lymphadenectomy and the quality of life in rectal cancer patients.Int Surg 1994;79:23–6.PubMedGoogle Scholar
  21. 21.
    Suzuki H, Matsumoto K, Koide A, Tada T, Fujin I, Okuda A, Shigemori C. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma.Surg Today 1994;24:85–7.PubMedGoogle Scholar
  22. 22.
    Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer.Dis Colon Rectum 1994;37:527–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer.Gastroenterology 1994;106:42–8.PubMedGoogle Scholar
  24. 24.
    Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. Bio-markers associated with prostate cancer progression.J Cellular Biochem Suppl 1994;19:208–16.Google Scholar
  25. 25.
    Koorey DJ, McCaughan GW. Tumour suppressor genes and colorectal neoplasia.J Gastroenterol Hepatol 1993;8:174–84.PubMedGoogle Scholar
  26. 26.
    Berger MS, Locher GW, Saurer S, Gullick WL, Waterfield MD, Groner B, Hynes NE. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.Cancer Res 1988;48:1238–43.PubMedGoogle Scholar
  27. 27.
    Williams AR, Piris J, Wyllie AH. Immunohistochemical demonstration of altered intracellular localization of the c-myc oncogene product in human colorectal cancer neoplasms.J Pathol 1990;160:287–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.Br J Cancer 1994;69:26–31.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 1996

Authors and Affiliations

  • Jia-Lin Yang
    • 1
  • Kim T. Ow
    • 2
  • Pamela J. Russell
    • 2
  • John M. Ham
    • 1
  • Philip J. Crowe
    • 1
  1. 1.Department of SurgeryPrince of Wales Hospital, University of New South WalesSydneyAustralia
  2. 2.Oncology Research CentrePrince of Wales Hospital, University of New South WalesSydneyAustralia

Personalised recommendations